All In Biotech

Drug Trial Radar · NCT06918925

First-In-Human Study to Evaluate Single and Multiple Ascending Doses of JUV-161 in Healthy Adult Volunteers

A Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single- and Multiple-ascending Doses of JUV-161 Administered Subcutaneously to Healthy Adult Volunteers.

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

72

Actual

Start

May 14, 2025

Primary completion

May 30, 2026

Study completion Sep 30, 2026

Sponsor

Lead sponsor
Juvena TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The present First-In-Human (FIH) study (JUV-161-101) aims to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple subcutaneous (SC) doses of JUV-161 in healthy volunteers. The study design is well-established for FIH studies and appropriate to assess the preliminary safety and tolerability of new drug candidates. Data from this study will support conduct studies in patients with DM1 as well as supporting studies in other degenerative myopathies and other disorders for which preclinical efficacy data have been obtained.JUV-161 has not been previously been administered to human subjects.

Conditions

  • Healthy Volunteer

Interventions

  • JUV-161, PlaceboDrug

    Single-Ascending, Placebo-Controlled

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse eventsTime frame: From enrollment through to safety follow-up Visit on Day 60
  2. Number of participants with treatment-emergent potentially clinically-significant safety abnormalities in safety laboratory parametersTime frame: From enrollment through to safety follow-up Visit on Day 60
  3. Number of participants who have changes from baseline in electrocardiogram values in QTcF intervalsTime frame: From enrollment through the safety follow-up visit on Day 60
  4. Number of participants who have changes from baseline in heart rate ( beats per minute)Time frame: From enrollment through the safety follow-up visit on Day 60
  5. Number of participants who have a change from baseline in systolic and diastolic blood pressure (mmHg)Time frame: From enrollment through the safety follow-up visit on Day 60

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Pty Ltd

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.